Rami Manochakian, M.D.

Closed for Enrollment

• A Randomized, Double-blind, Multiregional Phase 3 Study Of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy For The First-line Treatment Of Metastatic Non-small Cell Lung Cancer (HARMONi-3) Jacksonville, FL Rochester, MN

  This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.